CD226 and acute myeloid leukemia: Additionally, Allo15CAR33-NKT cells efficiently eliminate CD33- and CD1d- AML cells (e.g., THP1-FGCD33/CD1d-/-), and their killing capacity was diminished when NKRs (i.e., NKG2D and DNAM-1) were blocked, highlighting a reliance on an NKR-mediated targeting mechanism (Fig. 3f, g, and Supplementary Fig. 7a).